IL150463A0 - Compounds and methods for modulation of estrogen receptors - Google Patents

Compounds and methods for modulation of estrogen receptors

Info

Publication number
IL150463A0
IL150463A0 IL15046300A IL15046300A IL150463A0 IL 150463 A0 IL150463 A0 IL 150463A0 IL 15046300 A IL15046300 A IL 15046300A IL 15046300 A IL15046300 A IL 15046300A IL 150463 A0 IL150463 A0 IL 150463A0
Authority
IL
Israel
Prior art keywords
compounds
methods
disclosed
beta
same
Prior art date
Application number
IL15046300A
Other languages
English (en)
Original Assignee
Signal Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/492,939 external-priority patent/US6291456B1/en
Priority claimed from US09/611,156 external-priority patent/US6331562B1/en
Application filed by Signal Pharm Inc filed Critical Signal Pharm Inc
Publication of IL150463A0 publication Critical patent/IL150463A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15046300A 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors IL150463A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47577699A 1999-12-30 1999-12-30
US09/492,939 US6291456B1 (en) 1998-12-30 2000-01-27 Compounds and methods for modulation of estrogen receptors
US09/611,156 US6331562B1 (en) 1998-12-30 2000-07-06 Compounds and methods for modulation of estrogen receptors
PCT/US2000/035671 WO2001049673A2 (fr) 1999-12-30 2000-12-29 Composes et procedes de modulation de recepteurs d'oestrogenes

Publications (1)

Publication Number Publication Date
IL150463A0 true IL150463A0 (en) 2002-12-01

Family

ID=27413348

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15046300A IL150463A0 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors

Country Status (14)

Country Link
EP (1) EP1246814B1 (fr)
JP (1) JP2003519219A (fr)
KR (1) KR20020075388A (fr)
CN (1) CN1281598C (fr)
AT (1) ATE289300T1 (fr)
AU (1) AU781282B2 (fr)
CA (1) CA2396059A1 (fr)
DE (1) DE60018215T2 (fr)
DK (1) DK1246814T3 (fr)
ES (1) ES2238034T3 (fr)
HK (1) HK1058521A1 (fr)
IL (1) IL150463A0 (fr)
PT (1) PT1246814E (fr)
WO (1) WO2001049673A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
EP1177787A3 (fr) * 2000-07-28 2003-09-10 Pfizer Products Inc. Utilisation d'un agoniste/antagoniste estrogénique pour traiter la cataracte
EP1281710A1 (fr) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. Dérivés du 2H-1-benzopyrane, procédés de fabication et leurs compositions pharmaceutiques
US7148252B2 (en) * 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
WO2003044006A1 (fr) 2001-11-19 2003-05-30 Eli Lilly And Company Benzopyrans substitues convenant comme agonistes du recepteur aux oestrogenes beta
AU2005202072B2 (en) * 2001-11-29 2008-10-23 Gtx, Inc. Prevention and treatment of androgen-deprivation induced conditions
ES2319785T3 (es) * 2001-11-29 2009-05-12 Gtx, Inc. Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos.
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
NZ536291A (en) * 2002-04-19 2006-09-29 Signal Pharm Inc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
DE602004025460D1 (de) 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
MXPA05011243A (es) 2003-04-21 2005-12-15 Lilly Co Eli Benzopiranos substituidos como agonistas selectivos del receptor beta de estrogeno.
US7098340B2 (en) * 2003-05-14 2006-08-29 Warner Lambert Company Llc Benzyl sulfonamide derivatives
MXPA06002876A (es) * 2003-09-15 2006-06-05 Signal Pharm Llc Compuestos de benzopiranona, composiciones de los mismos y metodos de tratamiento que los utilizan.
EP1846386A2 (fr) * 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Utilisation de nouveaux derives de la coumarine comme agents d'ouverture de canaux ioniques
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
ME02474B (fr) 2010-05-12 2017-02-20 Radius Health Inc Schémas thérapeutiques
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
CN105801544A (zh) * 2016-04-18 2016-07-27 中国药科大学 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途
CN105801543B (zh) * 2016-04-18 2019-08-02 中国药科大学 4-芳香胺-香豆素衍生物及其制备方法和医药用途
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ａｒ＋乳癌の治療方法
CN106727637A (zh) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 一种治疗白内障的西药组合物及其用途
CN106492204A (zh) * 2016-12-27 2017-03-15 郑州郑先医药科技有限公司 一种治疗白内障的药物组合物
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1367297A (en) * 1996-01-11 1997-08-01 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
KR100615757B1 (ko) * 1998-12-30 2006-08-25 시그날 파마소티칼 아이엔씨 에스트로겐 수용체를 조절하는 화합물 및 방법

Also Published As

Publication number Publication date
WO2001049673A3 (fr) 2001-12-06
JP2003519219A (ja) 2003-06-17
CN1281598C (zh) 2006-10-25
CN1437591A (zh) 2003-08-20
DE60018215D1 (de) 2005-03-24
HK1058521A1 (en) 2004-05-21
KR20020075388A (ko) 2002-10-04
AU781282B2 (en) 2005-05-12
CA2396059A1 (fr) 2001-07-12
WO2001049673A2 (fr) 2001-07-12
ATE289300T1 (de) 2005-03-15
ES2238034T3 (es) 2005-08-16
EP1246814A2 (fr) 2002-10-09
AU3077101A (en) 2001-07-16
EP1246814B1 (fr) 2005-02-16
DE60018215T2 (de) 2006-02-09
DK1246814T3 (da) 2005-05-30
PT1246814E (pt) 2005-07-29

Similar Documents

Publication Publication Date Title
HK1058521A1 (en) Compounds and methods for modulation of estrogen receptors
WO2000055137A8 (fr) Composes et techniques de modulation des recepteurs des oestrogenes
HK1075893A1 (en) Compounds and methods for modulation of estrogen receptors
MY115784A (en) Estrogen agonists/antagonists
AU5467699A (en) Substituted isoxazole as estrogen receptor modulators
MX9505249A (es) Agonistas de estrogeno.
PT1492923E (pt) Composições de amido dilatado e látex para utilização no fabrico de papel
CR6478A (es) Moduladores del receptor glucocorticoide
WO2007016385A3 (fr) Utilisation des modulateurs du recepteur de la progesterone
BR0312024A (pt) Uso de derivados de ciclotiocarbamato no tratamento de condições relacionadas com hormÈnios
ATE292468T1 (de) Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
NZ500992A (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
LT2002031A (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
NO20020260L (no) 11<beta>-aryl-17,17-spirotiolansubstituerte steroider
Meyers The role of hormone receptors in estrogen activity is questionable
DK0898708T3 (da) Interaktion af cyclin D1 og estrogenreceptor og anvendelse deraf i assays
Charnock-Jones et al. Vascular endothelial growth factor and corpus luteum angiogenesis
MY137604A (en) Benzopyranone compounds, compositions thereof, and methods of treatment therewith
Novaro et al. A Cell Culture Model for Understanding Estrogen Receptor Regulation in Normal and Malignant Cells. Addendum
Ishii et al. A NEW THERAPEUTIC STRATEGY FOR TARGETING TUMOR STROMA IN HORMONE-REFRACTORY PROSTATE CANCER CELL GROWTH UNDER ANDROGEN ABLATION THERAPY